MK0869, aprepitant

DRUG6 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Major Depressive DisorderPostoperative Nausea and Vomiting

Phase 3

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)

CompletedNCT00035009

Merck Sharp & Dohme LLCMajor Depressive Disorder

Start: 2001-09-20End: 2004-03-24Updated: 2017-04-18

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)

CompletedNCT00035295

Merck Sharp & Dohme LLCMajor Depressive Disorder

Start: 2001-11-08End: 2003-12-05Updated: 2017-04-18

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)

CompletedNCT00034944

Merck Sharp & Dohme LLCMajor Depressive Disorder

Start: 2002-01-24End: 2003-12-17Updated: 2017-05-05

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)

CompletedNCT00042029

Merck Sharp & Dohme LLCMajor Depressive Disorder

Start: 2002-06-18End: 2003-10-03Updated: 2017-05-05

2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)

CompletedNCT00090246

Merck Sharp & Dohme LLCPostoperative Nausea and Vomiting

Start: 2004-05-13End: 2005-04-20Updated: 2017-05-05

2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)

CompletedNCT00090155

Merck Sharp & Dohme LLCPostoperative Nausea and Vomiting

Start: 2003-09-26End: 2004-11-24Updated: 2017-05-05